Mechanism of Targeting the MTOR Pathway to Regulate Ferroptosis in NSCLC with Different EGFR Mutations

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 May 16

PMID 38751752

Authors

Chunjiao Wu

Rui Zhong

Tianxue Wei

Yulong Jin

Chunying He

Hui Li

Ying Cheng

Affiliations

Soon will be listed here.

Abstract

Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating mutations can be treated with EGFR-tyrosine kinase inhibitors (TKIs). Although EGFR-TKI-targeted drugs bring survival promotion in patients with EGFR mutations, drug resistance is inevitable, so it is urgent to explore new treatments to overcome drug resistance. In addition, wild-type EGFR lacks targeted drugs, and new targeted therapies need to be explored. Ferroptosis is a key research direction for overcoming drug resistance. However, the role and mechanism of regulating ferroptosis in different EGFR-mutant NSCLC types remains unclear. In the present study, H1975 (EGFR T790M/L858R mutant), A549 (EGFR wild-type) and H3255 (EGFR L858R mutant) NSCLC cell lines were used. The expression of ferroptosis markers in these cell lines was detected using western blotting and reverse transcription-quantitative PCR. Cell viability was determined using the MTT assay and reactive oxygen species (ROS) levels were measured using flow cytometry. The results showed that, compared with EGFR wild-type/sensitive mutant cells, EGFR-resistant mutant cells were more sensitive to the ferroptosis inducer, erastin. Furthermore, the mammalian target of rapamycin (mTOR) inhibitor, everolimus (RAD001), induced cell death in all three cell lines in a dose-dependent manner. The ferroptosis inhibitor, ferrostatin-1, could reverse cell death in EGFR-resistant mutant and EGFR wild-type cells induced by RAD001, but could not reverse cell death in EGFR-sensitive mutant cells. Compared with EGFR wild-type/sensitive mutant cells, EGFR-resistant mutant cells were more sensitive to RAD001 combined with erastin. In addition, a high-dose of RAD001 reduced the expression levels of ferritin heavy-chain polypeptide 1 (FTH1), glutathione peroxidase 4 (GPX4) and ferroportin and significantly increased ROS and malondialdehyde (MDA) levels in EGFR-resistant mutant and EGFR wild-type cells. In the present study, GPX4 inhibitor only or combined with RAD001 inhibited the AKT/mTOR pathway in EGFR-resistant mutant cells. Therefore, the results of the present study suggested that inhibition of the mTOR pathway may downregulate the expression of ferroptosis-related proteins in EGFR-resistant and EGFR wild-type NSCLC cells, increase the ROS and MDA levels and ultimately induce ferroptosis.

References

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Liu Y, Wang Y, Liu J, Kang R, Tang D . Interplay between MTOR and GPX4 signaling modulates autophagy-dependent ferroptotic cancer cell death. Cancer Gene Ther. 2020; 28(1-2):55-63. DOI: 10.1038/s41417-020-0182-y. View

Prabowo A, Iyer A, Veersema T, Anink J, Schouten-van Meeteren A, Spliet W . BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol. 2013; 24(1):52-66. PMC: 8029322. DOI: 10.1111/bpa.12081. View

Hofmann M, Gerlach D, Misale S, Petronczki M, Kraut N . Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. 2022; 12(4):924-937. PMC: 9394389. DOI: 10.1158/2159-8290.CD-21-1331. View

Huang Y, Chen Y, Mei Q, Chen Y, Yu S, Xia S . Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds. Oncol Rep. 2013; 29(6):2486-92. DOI: 10.3892/or.2013.2357. View

Jung K, Kim S, Go H, Lee Y, Park M, Ko S . Synergistic Renoprotective Effect of Melatonin and Zileuton by Inhibition of Ferroptosis the AKT/mTOR/NRF2 Signaling in Kidney Injury and Fibrosis. Biomol Ther (Seoul). 2023; 31(6):599-610. PMC: 10616517. DOI: 10.4062/biomolther.2023.062. View

Yi J, Zhu J, Wu J, Thompson C, Jiang X . Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A. 2020; 117(49):31189-31197. PMC: 7733797. DOI: 10.1073/pnas.2017152117. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Ochi N, Takeyama M, Miyake N, Fuchigami M, Yamane H, Fukazawa T . The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics. Exp Cell Res. 2023; 424(1):113503. DOI: 10.1016/j.yexcr.2023.113503. View

10.

Badgley M, Kremer D, Maurer H, DelGiorno K, Lee H, Purohit V . Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020; 368(6486):85-89. PMC: 7681911. DOI: 10.1126/science.aaw9872. View

11.

Zhang Y, Swanda R, Nie L, Liu X, Wang C, Lee H . mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat Commun. 2021; 12(1):1589. PMC: 7952727. DOI: 10.1038/s41467-021-21841-w. View

12.

Lee J, Kim W, Bae K, Lee S, Lee E . Lipid Metabolism and Ferroptosis. Biology (Basel). 2021; 10(3). PMC: 8000263. DOI: 10.3390/biology10030184. View

13.

Lei G, Zhuang L, Gan B . mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential. Bioessays. 2021; 43(8):e2100093. DOI: 10.1002/bies.202100093. View

14.

Gkouvatsos K, Papanikolaou G, Pantopoulos K . Regulation of iron transport and the role of transferrin. Biochim Biophys Acta. 2011; 1820(3):188-202. DOI: 10.1016/j.bbagen.2011.10.013. View

15.

Singh S, Sadhukhan S, Sonawane A . 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188967. DOI: 10.1016/j.bbcan.2023.188967. View

16.

Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Tamiya N . Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study. Target Oncol. 2023; 18(5):657-665. DOI: 10.1007/s11523-023-00991-5. View

17.

Lou J, Zhao L, Huang Z, Chen X, Xu J, Tai W . Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine. 2020; 80:153370. DOI: 10.1016/j.phymed.2020.153370. View

18.

Thress K, Paweletz C, Felip E, Cho B, Stetson D, Dougherty B . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-2. PMC: 4771182. DOI: 10.1038/nm.3854. View

19.

Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y . Targeting mTOR for cancer therapy. J Hematol Oncol. 2019; 12(1):71. PMC: 6612215. DOI: 10.1186/s13045-019-0754-1. View

20.

Aylett C, Sauer E, Imseng S, Boehringer D, Hall M, Ban N . Architecture of human mTOR complex 1. Science. 2015; 351(6268):48-52. DOI: 10.1126/science.aaa3870. View